Astra guns for quick cancer and lupus filings
Questions about clinical data aside, Imfinzi and tremelimumab could be filed for first-line lung cancer by the end of the year.
Bristol might play a role in front-line lung cancer after all
The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
A change of the guard for the world’s biggest cancer companies
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Upcoming events – Roche braves liver cancer and Incyte looks for a new Jak
In liver cancer Roche hopes to succeed where Bristol failed, while Incyte tests its Jakafi follow-on in first-line graft-versus-host disease.
UCB goes to Ra for a complementary approach
The $2bn takeout of Ra Pharmaceuticals provides solace for investors bemoaning the biotech market’s poor performance.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Vantage Esmo 2019 roundup
Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical…
Esmo 2019 – mesothelioma trials contend with super-fast disease progression
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.